1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow CNV: new trials by email Literature Review of CNV trials Research Report on CNV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
| Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Combretastatin A-4 phosphate, Combretastatin A-4 Phosphate - Combretastatin A4 Phosphate, Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 8 | 2003-05-01 | 2017-12-06 |
Choroidal Neovascularization (2) · Macular Degeneration (2) · Eye Diseases (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Wet Macular Degeneration (1)
Choroid Diseases (2) · Metaplasia (2) · Neovascularization, Pathologic (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Uveal Diseases (2) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Retinal Degeneration (1) · Retinal Diseases (1)
Ranibizumab (1) · fosbretabulin (1)
AbbVie (1) · Johns Hopkins University (1)
United States (2)